The total return over the past 12 months is -38.64% vs. +16.94% for the S&P 500. So far it's up -35.79% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (38.64%) | +33.28% | N/A | N/A | N/A | N/A |
| Total Return CAGR | (38.64%) | +33.28% | N/A | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Mineralys Therapeutics, Inc. (MLYS)
| Year | Start price | End price | MLYS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $36.29 | $23.30 | (35.79%) | +14.51% | (50.30%) |
| 2025 | $12.31 | $36.29 | +194.80% | +17.72% | +177.08% |
| 2024 | $8.60 | $12.31 | +43.14% | +24.89% | +18.25% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
